On December 31st, NCCS submitted our final comment letter of the year to the Centers for Medicare and Medicaid Services regarding the advance notice of proposed rulemaking for the Medicare Part B drug program.In the letter, we outlined concerns that this proposal could have on Medicare beneficiaries such as impacts on patient access to innovative therapies, as well as concerns regarding the enormous scope of the test. NCCS suggested a more modest test with aggressive evaluation standards. We also recommended that the new Part B test should be coordinated with the ongoing Oncology Care Model demonstration project.
NCCS also joined the Cancer Leadership Council in a letter regarding the proposal. Read the full NCCS and CLC letters below.